REG - RTW Biotech Opp. - Royalty Funding Agreement with Savara Inc.

RTW Biotech OpportunitiesAnnouncement

31/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251031:nRSe5854Fa&default-theme=true

RNS Number : 5854F  RTW Biotech Opportunities Ltd  31 October 2025

LEI: 549300Q7EXQQH6KF7Z84

31 October 2025

RTW Biotech Opportunities Ltd

Royalty Funding Agreement with Savara Inc.

·      Savara announces $75m funding agreement with funds managed by RTW

·      Subject to FDA approval of MOLBREEVI, a treatment for rare lung
disease

·      RTW Bio will participate through its investment in 4010 Royalty
Fund

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the announcement by Savara, Inc. ("Savara" Nasdaq: SVRA) that it has
entered into a $75 million royalty funding agreement with funds managed by RTW
Investments, LP.  RTW Bio will participate in this investment through its
commitment to the RTW-managed 4010 Royalty Fund. Savara is a clinical stage
biopharmaceutical company focused on rare respiratory diseases.

 

The funding is subject to FDA approval of Savara's lead program, MOLBREEVI, a
treatment in Phase 3 development for autoimmune pulmonary alveolar proteinosis
(autoimmune PAP), a rare disease characterised by the abnormal build-up of
surfactant in the alveoli of the lungs. Assuming FDA approval, the funding
will support the U.S. launch and further commercialisation of MOLBREEVI, which
would be the first approved drug for autoimmune PAP.

 

Rod Wong, CIO of RTW Investments, said, "The pivotal clinical trial
demonstrated the potential of MOLBREEVI to treat autoimmune PAP and this
investment reflects our confidence in Savara and the strong commercial
potential of the therapy. We are proud to partner with the Savara management
team and look forward to supporting their efforts to bring this meaningful
treatment to patients."

 

Savara's announcement can be found here
(https://investors.savarapharma.com/news/news-details/2025/Savara-announces-75M-Royalty-Funding-Agreement-with-RTW-to-Support-the-Potential-Launch-of-MOLBREEVI-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Woody Stileman

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAXEEDLSSFFA



            Copyright 2019 Regulatory News Service, all rights reserved